Researchers develop artificial building blocks of life
For the first time, scientists have developed artificial nucleotides, the building blocks of DNA, with several additional properties in the laboratory
Stephanie Kath-Schorr
Artificial nucleic acids differ in structure from their originals. These changes affect their stability and function. “Our threofuranosyl nucleic acid is more stable than the naturally occurring nucleic acids DNA and RNA, which brings many advantages for future therapeutic use,” said Professor Dr Stephanie Kath-Schorr. For the study, the 5-carbon sugar deoxyribose, which forms the backbone in DNA, was replaced by a 4-carbon sugar. In addition, the number of nucleobases was increased from four to six. By exchanging the sugar, the TNA is not recognized by the cell's own degradation enzymes. This has been a problem with nucleic acid-based therapeutics, as synthetically produced RNA that is introduced into a cell is rapidly degraded and loses its effect. The introduction of TNAs into cells that remain undetected could now maintain the effect for longer. “In addition, the built-in unnatural base pair enables alternative binding options to target molecules in the cell,” added Hannah Depmeier, lead author of the study. Kath-Schorr is certain that such a function can be used in particular in the development of new aptamers, short DNA or RNA sequences, which can be used for the targeted control of cellular mechanisms. TNAs could also be used for the targeted transport of drugs to specific organs in the body (targeted drug delivery) as well as in diagnostics; they could also be useful for the recognition of viral proteins or biomarkers.
Original publication
Other news from the department science
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.